Recombinant Zoster Vaccine (Shingrix): a nex gun for Rheumatologist
Beyond Rheumatology 2022;
4
(1)
: e375
DOI: 10.53238/br_20223_375
Topic: Vaccination
Category: Editorial
Abstract
Herpes Zoster, or as commonly known shingles, is a debilitating painful rash occurring at any age in anyone caused by reactivation of the varicella zoster virus (VZV). The lifetime risk of HZ in the general population is around 30% HZ incidence increases with age and is estimated that 90% of adults have contracted VZV and are therefore at risk of developing HZ and that at least 1 in 3 individuals will develop the disease in their lifetime. Increased HZ incidence, attributed to a decline in immunity, is observed in elderly people and in patients using immunosuppressive medications. In light of the significant burden caused by HZ and its complications in frail patients, adopting a preventive strategy seems promising, particularly using vaccination in appropriate age and risk groups.
To cite this article
Recombinant Zoster Vaccine (Shingrix): a nex gun for Rheumatologist
Beyond Rheumatology 2022;
4
(1)
: e375
DOI: 10.53238/br_20223_375
Publication History
Submission date: 11 Jan 2022
Revised on: 08 Feb 2022
Accepted on: 24 Feb 2022
Published online: 18 Jul 2022
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.